Treatment Strategies for Dosing the Second Generation Antipsychotics

CNS Neuroscience and Therapeutics

Volumn 17, Issue 2, 2011, Pages 110-117

  Schwartz, Thomas L ^a   Stahl, Stephen M ^b,c  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Atypical antipsychotics; Bipolar disorder; Depression; Schizophrenia; Second generation Antipsychotics

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; FLUOXETINE; ILOPERIDONE; MIRTAZAPINE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANXIETY DISORDER; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; BODY WEIGHT; BOOK; DEPRESSION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR DEPRESSION; MANIA; MEDICAL PRACTICE; MEDLINE; MENTAL DISEASE; PATIENT MONITORING; PHARMACODYNAMICS; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT PLANNING;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEDLINE; SCHIZOPHRENIA;

EID: 79952648261     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2011.00234.x     Document Type: Article

References (91)

1. Citrome L, Jaffe A, Levine J. Dosing of second generation antipsychotic medication in a state hospital system. J Clin Psychopharm 2005;25:388-390.
2. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: A review of the current evidence. Harv Rev Psychiatry 2002;10:280-291.
3. Olanzapine (ZyprexaTM) FDA Package Insert.
4. Quetiapine (SeroquelTM) FDA Package Insert.
5. Aripiprazole (AbilifyTM) FDA Package Insert.
6. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: Second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008;28:156-165.
7. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H; Moonstone Study Group. Extended release quetiapine fumarate monotherapy for major depressive disorder: Results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009;14:299-313.
8. Sadock BJ, Sadock VA, editors. Kaplan and Sadock's synopsis of psychiatry, 9th ed. Philadelphia Lippincott Williams & Wilkins, 2003.
9. Eltanaihi-Furtmüller N, Hummer M, Fleischhacker WW. Switching between second-generation antipsychotics: Why and how? CNS Drugs 2005;19:27-42.
10. Stahl SM. Stahl's essential psychopharmacology: Neuroscientific basis and practical applications, 3rd ed. Cambridge :Cambridge University Press, 2008.
11. Zhang W. Bymaster FP The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Psychopharmacology 1999;141:267-278.
12. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88, 059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-113.
13. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101.
14. Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG. The role of 5-HT2A receptors in antipsychotic activity. Life Sci. 1995;56:2209-2222.
15. Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: A double-blind randomized placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1879-1883. Epub 2008 Sep 4.
16. Haas M, Unis AS, Armenteros J, Copenhaver MD, Quiroz JA, Kushner SF. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009;19:611-621.
17. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. Br J Psychiatry 2005;187:229-234.
18. Scott LJ, Dhillon S. Risperidone: A review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs 2007;9:343-354.
19. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychoticmajor depression. J Psychiatr Res 2009;43:205-214.
20. Yoshimura R, Umene-Nakano W, Ueda N, Ikenouchi-Sugita A, Hori H, Nakamura J. Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline. Human Psychopharmacol. 2008;23:707-713.
21. Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X, Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: A randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008;69:1228-1336.
22. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry 2008;64:527-532.
23. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-829.
24. Paliperidone(Invega TM), FDA Package Insert, 2008.
25. Risperidone(RisperdalTM), FDA Package Insert, 1995.
26. McEvoy JP, Lieberman JA, Stroup TS, et al. CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-610.
27. Kryzhanovskaya L, Schulz SC, McDougle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48:60-70.
28. Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007;164:1547-1556.
29. Citrome L, Kantrowitz JT. Olanzapine dosing above the licensed range is more efficacious than lower doses: Fact or fiction? Expert Rev Neurotherapeutics 2009;9:1045-1058.
30. Citrome L, Stauffer VL, Kinon BJ, et al. Olanzapine plasma concentrations after treatment with 10, 20, 40mg/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacology 2009;29:278-283.
31. Kinon BJ, Volvaka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed dose study. J Clin Psychopharmacology 2008;28:392-400
32. Mathews J, Garcia KS, Mintun MA, Sheline YI. Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: A pilot study. Psychiatry Res 2006;146:149-155. Epub 2006 Mar 3.
33. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: A pilot study. J Psychopharmacol 2002;16:365-368.
34. Corya SA, Perlis RH, Keck PE Jr., Lin DY, Case MG, Williamson DJ, Tohen MF. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 2006;67:798-806.
35. Croxtall JD, Scott LJ. Olanzapine/fluoxetine: A review of its use in patients with treatment-resistant major depressive disorder. CNS Drugs 2010;24:245-262, doi:.
36. Cutler A, Ball S, Stahl SM. Dosing Atypical antipsychotics. CNS Spectr 2008;13(5 Suppl 9):1-16.
37. Holt RI, Peveler RC. Obesity, serious mental illness and antipsychotic drugs. Diabetes Obes Metab 2009;11:665-679.
38. Treuer T, Hoffmann VP, Chen AK, et al. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: Results from a six-month prospective, multinational, observational study. World J Biol Psychiatry 2009;10(4 Pt 3):729-740.
39. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. PharmacolTher 2010;125:169-179.
40. Monteleone P, Martiadis V, Maj M. Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Psychiatr Clin N Am 2009;32:775-794.
41. Nguyen D, Brakoulias V, Boyce P. An evaluation of monitoring practices in patients on second generation antipsychotics. Australasian Psychiatry 2009;17(4):295-299.
42. Newcomer JW. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. J Clin Psychiatry 2009;70 (Suppl 3):30-36.
43. Patel JK, Buckley PF. Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA; CAFE Investigators. Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study. Schizophr Res 2009;111:9-16.
44. Peuskens J, Trivedi JK, Brecher M, Miller F. Study 4 Investigators. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: Post-hoc analysis of data from a randomized withdrawal, placebo-controlled study. Int Clin Psychopharmacol 2010;25:183-187.
45. Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: Combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005;21:923-934.
46. Stahl SM. Essential psychopharmacology: The prescriber's guide. 3rd ed. Cambridge University Press: Cambridge, 2009.
47. Citrome L, Jaffe A, Levine J. The ups and downs of dosing second generation antipsychotics. Psychiatr Serv 2007;58:11.
48. Citrome L, Jaffe A, Levine J, Lindenmayer JP. Dosing of quetiapine in schizophrenia: How clinical practice differs from registration studies. J Clin Psychiatry 2005;66:1512-1516.
49. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121:106-115. Epub 2009 Nov 8.
50. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: Results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70:540-549. Epub 2009 Apr 7.
51. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 2010;13:305-320. Epub 2009 Aug 20.
52. Gao K, Sheehan DV, Calabrese JR. Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. Expert Rev Neurother 2009;9:1147-1158.
53. Wang HN, Peng Y, Tan QR, et al. Quetiapine ameliorates anxiety-like behavior and cognitive impairments in stressed rats: Implications for the treatment of posttraumatic stress disorder. Physiol Res 2010;59:263-271. Epub 2009 Jun 19.
54. Nyberg S, Widzowski D. Translational pharmacology of quetiapine and norquetiapine: Preclinical findings support multifunctional psychotropic properties. Eur Psychiatry 2010;25(Suppl. 1):1446.
55. Scharf M, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: A randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2008;69:1557-1564. Epub 2008 Oct 7.
56. Jahanshahi A, Lim LW, Steinbusch HW, Visser-Vandewalle V, Temel Y. Buspirone-induced changes in the serotonergic and non-serotonergic cells in the dorsal raphe nucleus of rats. Neurosci Lett 2010;473:136-140. Epub 2010 Feb 21
57. Shajahan P, Taylor M. The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice. J Psychopharmacol 2010;24:565-572. Epub 2009 Jan 22.
58. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: A randomized, placebo-controlled pilot study. Depress Anxiety 2007;24:487-494.
59. Keck PE Jr., McElroy SL, Arnold LM. Ziprasidone: A new atypical antipsychotic. Expert Opin Pharmacother 2001;2:1033-1042.
60. Warrington L, Lombardo I, Loebel A, Ice K. Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. CNS Drugs 2007;21:835-849.
61. Ziprasidone (GeodonTM) FDA Package Insert, Pfizer. 2001.
62. Citrome L, Reist C, Palmer L, et al. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Schizophr Res 2009;115:115-120.
63. Citrome L, Jaffe A, Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J Clin Psychiatry 2009;70:975-982.
64. Stahl SM, Shayegan D. The psychopharmacology of ziprasidone: Receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003;64(supplement 19):6-12.
65. Shayegan DK, Stahl SM. Atypical Antipsychotics: Matching receptor profile to individual patient's clinical profile. CNS Spectrums 2003;9(10 Suppl 11):6-14.
66. Stahl SM, Lombardo I, Loebel A, Mandel F. Efficacy of Ziprasidone in Dysphoric Mania: Pooled analysis of 2 double blind studies. J Affect Disord 2010;122:doi:.
67. Cutler A, Sara Ball, Stephen M. Stahl. Expert review supplement dosing atypicals antipsychotics. CNS Spectrums 2008;13(5 Suppl 9):1-14.
68. Liebowitz MR, Salman E, Mech A, Dunner D, Johnson AE, Akhtar J, Pratap R. Ziprasidone monotherapy in bipolar II depression: An open trial. J Affect Disord 2009;118:205-208.
69. Rosa AR, Franco C, Torrent C, et al. Ziprasidone in the treatment of affective disorders: A review. CNS Neurosci Ther 2008;14:278-286.
70. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychopharmacol 2004;65:217-221.
71. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol 2005;25:497-499.
72. Dunner DL, Amsterdam JD. Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: A randomized, open-label, pilot study. J Clin Psychiatry 2007;68:1071-1077.
73. Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials. Clin Ther 2009;31(Pt 1):1345-1359.
74. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clin Ther 2010;32(Suppl 1):S3-S20.
75. Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. B J Psychiatry 2009;194:40-48.
76. Arbaizar B, Dierssen-Sotos T, Gomez-Acebo I, Llorca J. Aripiprazole in major depression and mania: Meta-analyses of randomized placebo-controlled trials. Gen Hosp Psychiatry 2009;31:478-483.
77. Nelson JC, Mankoski R, Baker RA, Carlson BX, Eudicone JM, Pikalov A, Tran QV. Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-hoc, pooled analysis of two large, placebo-controlled studies. Berman RM. J Affect Disord 2010;120:133-140.
78. Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48:1110-1119.
79. Hoge EA. Worthington JJ 3rd. Kaufman RE, Delong HR, Pollack MH, Simon NM. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. Cns Spectrums 2008;13:522-527.
80. Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol 2007;27:207-210.
81. Asenapine (Saphris TM) FDA Package Insert. 2009.
82. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. J Affect Disord 2010;122:27-38.
83. Tarazi FI, Shahid M. Asenapine maleate: A new drug for the treatment of schizophrenia and bipolar mania. Drugs of Today 2009;45:865-876.
84. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68:1492-1500.
85. Franberg O, Marcus MM, Ivanov V, Schilstrom B, Shahid M, Svensson TH. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology 2009;204:251-264.
86. Iloperidone (Fanapt TM) FDA Package Insert. Vanda Pharmaceuticals. 2009.
87. Potkin SG, Litman RE, Torres R, Wolfgang CD. Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. J Clin Psychopharmacol 2008;28(2 Suppl 1):S4-S11.
88. Kalkman HO, Feuerbach D, Lotscher E, Schoeffter P. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors. Life Sci. 2003;73:1151-1159.
89. Scott LJ. Iloperidone: In schizophrenia. CNS Drugs 2009;23:867-880.
90. Cutler AJ. Iloperidone: A new option for the treatment of schizophrenia. Expert Rev Neurotherapeutics 2009;9:1727-1741.
91. Stahl SM. Multifunctional drugs: A novel concept for psychopharmacology. Cns Spectrums 2009;14:71-73.